Actively Recruiting

Age: 19Years +
All Genders
NCT06603558

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

Led by AbbVie · Updated on 2026-01-20

3000

Participants Needed

4

Research Sites

240 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

CONDITIONS

Official Title

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with migraine suitable for treatment with atogepant according to the latest approved local label
  • Participants prescribed atogepant in accordance with the approved local label
Not Eligible

You will not qualify if you...

  • Participants with any contraindication to atogepant as listed on the latest approved local label
  • Participants currently participating in another clinical research except observational study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Hallym University Dongtan Sacred Heart Hospital /ID# 273581

Hwaseong, Gyeonggido, South Korea, 18450

Actively Recruiting

2

Seoul National University Hospital /ID# 271892

Seoul, Seoul Teugbyeolsi, South Korea, 03080

Actively Recruiting

3

Kangbuk Samsung Hospital /ID# 271893

Seoul, Seoul Teugbyeolsi, South Korea, 03181

Actively Recruiting

4

Yonsei University Health System Severance Hospital /ID# 272639

Seoul, Seoul Teugbyeolsi, South Korea, 03722

Actively Recruiting

Loading map...

Research Team

C

Celine Im

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine | DecenTrialz